Twilight of ESA Monopoly as New Anemia Options Advance
For more than 20 years, erythropoiesis-stimulating agents (ESAs) have dominated the anemia field. But this month's advisory committee win by Affymax Inc.'s peginesatide, as well as new data coming out of the American Society of Nephrology's Kidney Week and the American Society of Hematology's annual meeting, indicate big changes are afoot – changes that impact competitors not only in the ESA space but in the iron-replacement space as well.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST